

24 July 2025

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Q4 FY25 Quarterly Activities Report

Melbourne, Victoria | Alcidion Group Limited (ASX:ALC) ('Alcidion' or the 'Company') has today released its Appendix 4C and Quarterly Activities Report for the quarter ended 30 June 2025 (Q4 FY25).

Highlights:

- Q4 FY25 positive operating cashflow of \$7.4M, record quarter for the business
 - Record quarterly cash receipts of \$22.4M (\$18.6M pcpc (prior corresponding period))
- FY25 positive operating cashflow of \$5.8M (a \$12.9M improvement on the PCP operating cash flow loss of \$7.1M)
- Record annual receipts of \$50.9M (PCP: \$43.9M)
- Q4 new TCV sales of \$6.7M, including:
 - Expansion of North Cumbria contract (NCIC) to include clinical communications
 - Expansion of Hume contract to include additional sites
 - Expansion of the NT contract to include team messaging
 - Several existing contract renewals and smaller incremental new sales
- FY25 new TCV sales of \$73.8M, up 109% on pcpc
- Cash balance of \$17.7M and no debt as of 30 June 2025
- Reconfirming FY25 EBITDA guidance to exceed \$4.5M

Alcidion CEO and Managing Director, Kate Quirke said: "This quarter was a very strong one for Alcidion, continuing the momentum demonstrated across FY2025 in all areas of the business, notably new sales, contract expansions, deployments, and cashflow."

"In Q4 we generated positive operating cashflow of \$7.4M, the highest quarterly positive cashflow in the company's history, which resulted in a full year positive operating cashflow of \$5.8M, also a record result for the business."

"We signed several expansions to existing contracts in this quarter - notably with Hume, NALHN and NT Health – thereby progressively increasing the overall value of those contracts. These expansions further demonstrate the value proposition of our Miya Precision platform and the flexibility and ease by which our customers can add new modules as appropriate for their capability requirements and/or budget availability."

"Specifically, we further expanded our contract with North Cumbria Integrated Care NHS Trust to include our clinical communications module. This now takes the total combined TCV to over \$39M which shareholders will recall is for the deployment of Miya Precision as their new EPR solution."

Kate Quirke, continued: "We reconfirm our recently upgraded guidance to deliver FY25 EBITDA exceeding \$4.5M."

We end the year with \$17.7M of cash and no debt. Our recurring revenue base continues to build and with each new contract expansion we increasingly demonstrate the long-term value proposition of the business.”


Financial Update

Alcidion generated Q4 new sales of \$6.7M of which approximately 73% is recurring product revenue and 27% is non-recurring services (primarily product implementation) revenue.

Cash receipts from customers in Q4 were \$22.4M, which includes the payment from NCIC for the upfront capital licence component, with record positive operating cashflow of \$7.4M. This resulted in a FY25 positive operating cashflow of \$5.8M, a material improvement of \$12.9M compared to the operating cashflow loss of \$7.1M in FY24.

Staff cash costs increased slightly in Q4, a result of the payment of 50% of the FY25 Short-term incentives (STI) which were achieved during the year. The balance of these STI payments will be made in Q1 FY26.

‘Other’ payments of \$4.3M relate to VAT / GST payments made during the quarter and align to the material customer cash receipts collected during the quarter. As a result of the material VAT / GST payments made in Q4, ‘Other’ payments in Q1 FY26 are expected to be lower than in prior years.



As noted in item 6 of the Company’s Appendix 4C, payments made to related parties and their associates totalled \$0.33M for the quarter. These payments relate solely to Director’s remuneration.

Outlook

Alcidion reconfirms guidance for FY25 EBITDA to exceed \$4.5M.

Following several material new contracts in FY25, Alcidion continues to progress new and expansion contract opportunities with increasing momentum. In addition, Alcidion continues to deploy (implement) the Miya platform across several contracts won in FY25, notably at North Cumbria and Hywel Dda, with those deployments continuing throughout FY26.

The Company will provide an update on FY26 contracted revenue and financial guidance as part of the full year FY25 results which are scheduled to be released to the ASX on 28 August 2025.

Investor Webcast

Alcidion Group Managing Director Kate Quirke will host a webcast with investors via Zoom on Thursday, 24 July 2025 at 10:30am Australian Eastern Standard Time (AEST).

To register for the webcast, please follow this link:

https://us02web.zoom.us/webinar/register/WN_XifhYx6bQYe8SJYr7LM2dw

Registered participants will receive an email containing the Zoom access link and phone dial-in details.

ENDS

Authorised for ASX release by the Board of Directors of Alcidion Group Limited

For further information, please contact:

Investor Relations

investor@alcidion.com

About Alcidion

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2025

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

ALCIDION GROUP LIMITED

ABN

77 143 142 410

Quarter ended ("current quarter")

30 June 2025

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities			
1.1 Receipts from customers		22,370	50,858
1.2 Payments for			
(a) research and development		-	-
(b) product manufacturing and operating costs		(2,023)	(5,724)
(c) advertising and marketing		(660)	(1,137)
(d) leased assets		-	-
(e) staff costs		(6,704)	(25,579)
(f) administration and corporate costs		(1,405)	(5,205)
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		69	148
1.5 Interest and other costs of finance paid		(20)	(81)
1.6 Income taxes paid		-	-
1.7 Government grants and tax incentives		-	-
1.8 Other – GST/VAT received/(paid)		(4,276)	(7,517)
1.9 Net cash from / (used in) operating activities		7,351	5,763
2. Cash flows from investing activities			
2.1 Payments to acquire or for:			
(g) entities		-	-
(h) businesses		-	-
(i) property, plant and equipment		(115)	(125)
(j) investments		-	-
(k) intellectual property		-	-
(l) other non-current assets		-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(115)	(125)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Payment for principal portion of lease liabilities)	(208)	(764)
3.10	Net cash from / (used in) financing activities	(208)	(764)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	10,186	11,798
4.2	Net cash from / (used in) operating activities (item 1.9 above)	7,351	5,763
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(115)	(125)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(208)	(764)
4.5	Effect of movement in exchange rates on cash held	483	1,025
4.6	Cash and cash equivalents at end of period	17,697	17,697

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	17,376	9,743
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (TDs)	321	443
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	17,697	10,186

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	334
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	150	37
7.4	Total financing facilities	150	37
7.5	Unused financing facilities available at quarter end		113
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. WBC corporate credit card facility secured against cash deposits; interest charged at 14.25% on overdue accounts		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	7,351
8.2	Cash and cash equivalents at quarter end (item 4.6)	17,697
8.3	Unused finance facilities available at quarter end (item 7.5)	113
8.4	Total available funding (item 8.2 + item 8.3)	17,810
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 24 July 2025

Authorised by: The Board of Directors

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.